

Media Release

FOR IMMEDIATE RELEASE

Contact Synosia Therapeutics

In Europe

Julie Walters at Tudor Reilly

Tel: +44 (0) 1494 753 990

Mobile +44 (0) 775 3626967

julie.walters@tudor-reilly.com

In the US

Michele Parisi at Tudor Reilly

Tel: +1 925 864 5028

michele.parisi@tudor-reilly.com

In Switzerland

Martin Meier-Pfister or Jan Gregor at

IRF Communications

Tel: +41 43 244 8154

Mobile: +41 79 652 3620

synosia@irfcom.ch

Synosia Therapeutics Announces Appointment of Vice President of Neuropharmacology

Basel, Switzerland, September 3, 2008 – Synosia Therapeutics today announced the appointment of Dr Hans-Rudolf Olpe to the position of Vice President of Neuropharmacology, effective immediately.

Dr Olpe, who joins the Basel office, has over 35 years experience working in neuropharmacology and neurobiology in academia and industry. At Ciba, he served as head of the nervous system pharmacology department and subsequently head of the stroke and epilepsy department at Novartis, where his team developed rufinamide, one of the leading compounds now in the Synosia portfolio, and the seizure medication Trileptal®. He also worked as team leader of the European branch of the International Consortium on Borderline Personality Disorder, working with the Nobel Laureate Professor Eric Kandel.

During his time at Novartis, Olpe pioneered the company's use of imaging and biomarkers in pre-clinical neuroscience research to identify which would be the most successful candidates to take forward into further development.

Commenting on his appointment, Synosia Chief Executive Officer and President, Ian Massey said: "Dr Olpe's experience in neuropharmacology and his innovative approach to research will make a valuable contribution to our team, particularly his experience as a pioneer of many of the imaging techniques that help to inform our proof-of-mechanism studies."

“Synosia has an impressive portfolio full of interesting compounds,” said Dr Olpe. “This is an exciting company with an attractive business philosophy and I look forward to developing the potential of these novel therapies for unmet medical needs in psychiatry and neurology.”

Olpe was educated at the University of Basel and also held post-doctoral training positions at the Mario Negri Institute, Milano and The Rockefeller University, New York. He has held academic positions as guest scientist at the Neurological Hospital of Zurich and the University of California Irvine, Lecturer at the Biocentre of the University of Basel and Member of the Medical Faculty of the University of Basel.

About Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialise innovative and clinically differentiated products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through key partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson’s disease. Synosia’s headquarters is in Basel, Switzerland. For more information visit www.synosia.com

Disclaimer

This communication, and oral statements made with respect to information contained in this communication, expressly or implicitly contains certain forward-looking statements concerning Synosia Therapeutics and its business. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to our plans for our regulatory filings, enrolment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words “potential”, “could” and similar expressions also identify forward-looking statements. These statements are based upon management’s current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the respective regulatory agencies refuse approval of our applications, the outcome of any discussions with such regulatory agencies and unexpected delays in preparation of materials for submission to such respective regulatory agencies as a part of our filings.

Synosia Therapeutics is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward-looking statements.

ENDS

www.synosia.com

In Europe: +44 (0) 1494 753990; In Switzerland: +41 43 244 8154; In the US: + 1 925 864 5028